☆ 4.7 Review

Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review

JOURNAL OF MEDICAL VIROLOGY (2022)

Related references

Note: Only part of the references are listed.

Letter Oncology

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Cong Zeng et al.

CANCER CELL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Wilfredo F. Garcia-Beltran et al.

Summary: Recent surveillance has identified the emergence of the SARS-CoV-2 Omicron variant, which carries up to 36 mutations in the spike protein and has the potential to evade vaccine-induced immunity. This study found that individuals vaccinated with mRNA vaccines exhibited strong neutralization of the Omicron variant, while most vaccinees had weak neutralization. The study also revealed that the Omicron variant infects more efficiently than other tested variants.

CELL (2022)

Add to Collection

Article Medicine, General & Internal

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Emma K. Accorsi et al.

Summary: Assessing the performance of COVID-19 vaccines against the Omicron variant is crucial for public health guidance. This study found that receiving three doses of mRNA COVID-19 vaccine was associated with a lower likelihood of symptomatic SARS-CoV-2 infection compared to being unvaccinated or receiving two doses. These findings suggest that three doses of mRNA vaccine provide protection against both Omicron and Delta variants, though the protection against Omicron may be slightly lower.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Medicine, General & Internal

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens et al.

Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.

LANCET (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Jingxin Li et al.

Summary: The study suggests that additional COVID-19 vaccine doses may be needed for individuals who initially received CoronaVac. Heterologous boosting with Convidecia, a recombinant adenovirus type 5 (AD5)-vectored vaccine, was found to be safe and more immunogenic than homologous boosting with CoronaVac in adults previously vaccinated with CoronaVac.

NATURE MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Eddy Perez-Then et al.

Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Homologous and Heterologous Covid-19 Booster Vaccinations

R. L. Atmar et al.

Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Nick Andrews et al.

Summary: A study conducted in England showed that vaccines against SARS-CoV-2 provide high protection against hospitalization and death from Covid-19 at 20 weeks or more after vaccination. However, the effectiveness of the vaccines decreases over time, especially in individuals aged 65 and older and those with underlying risk factors.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Ital Nemet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Rolando Pajon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cell Biology

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

John P. Evans et al.

Summary: The declining efficacy of SARS-CoV-2 vaccines and the emergence of variants resistant to vaccine-induced immunity have sparked a debate on the need for booster vaccine doses. A study found that the Omicron variant spike protein can almost completely escape neutralizing antibodies produced by recipients of only two mRNA vaccine doses.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine

Tal Patalon et al.

Summary: This study demonstrated that receiving a booster dose of the BNT162b2 vaccine can reduce the odds of testing positive for SARS-CoV-2 in the short term, potentially counteracting waning immunity. Further monitoring is needed to determine the duration of immunity following the booster dose.

JAMA INTERNAL MEDICINE (2022)

Add to Collection

Article Immunology

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies

Xun Wang et al.

Summary: This study found that the Omicron variant is highly resistant to neutralization by sera from convalescents or individuals vaccinated with two doses of inactivated whole-virion vaccines. However, a homologous or heterologous booster significantly increased neutralization titers. Additionally, the Omicron variant resists most monoclonal antibodies targeting distinct epitopes. These findings highlight the importance of pushing forward booster vaccinations to combat emerging SARS-CoV-2 variants.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

Article Immunology

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents

Chengbao Ma et al.

Summary: The heavily mutated SARS-CoV-2 Omicron variant has raised global concern due to its emergence and rapid transmission. This study compared the infectivity, membrane fusion, and immune escape efficiency of the Omicron variant with the original strain and the Delta variant. The results showed that the Omicron variant had slightly higher infectivity and a significantly reduced fusogenicity compared to the Delta variant. Neutralization assays revealed a dramatic reduction in neutralization against the Omicron variant, but immune-boosting through three vaccine shots improved immunity against it.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Letter Cell Biology

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination

Xiaoqi Yu et al.

CELL DISCOVERY (2022)

Add to Collection

Article Multidisciplinary Sciences

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

Chengzi Kaku et al.

Summary: Heterologous prime-boost immunization strategies have the potential to enhance the efficacy of COVID-19 vaccines. A study found that heterologous vaccination induced stronger neutralizing antibody and memory B cell responses, as well as better efficacy against variant strains. The study also revealed that heterologous vaccination can enhance the quality of B cell responses.

SCIENCE (2022)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Noam Barda et al.

Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar-On et al.

Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

Eli S. Rosenberg et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

© Peeref 2019-2024. All rights reserved.